Related Experiment Videos
Carvedilol: use in chronic heart failure
Robert Neil Doughty1, Harvey D White
1Department of Medicine, Faculty of Medical and Health Sciences, Level 12, Auckland Hospital Support Building, Park Road, Auckland, New Zealand. r.doughty@auckland.ac.nz
Expert Review of Cardiovascular Therapy
|December 26, 2006
Summary
Carvedilol, a beta-blocker with vasodilatory effects, significantly improves survival and reduces hospitalizations in patients with chronic heart failure. Its benefits extend to those with comorbidities like diabetes and renal failure, making it a recommended therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Carvedilol is a beta-adrenergic antagonist with alpha1-antagonism, widely studied for heart failure treatment.
- It impacts left-ventricular (LV) function and remodeling in heart failure patients.
Purpose of the Study:
- To summarize the evidence supporting carvedilol's efficacy and safety in heart failure management.
- To highlight its role in improving survival and reducing hospitalizations.
Main Methods:
- Review of large-scale randomized, placebo-controlled trials involving over 4000 patients.
- Analysis of comparative studies with other beta-blockers like metoprolol.
- Assessment of carvedilol's impact on LV ejection fraction and remodeling.
Main Results:
- Carvedilol improves left-ventricular ejection fraction and attenuates LV remodeling over 6-12 months.
- Large trials show carvedilol improves survival and reduces hospitalizations in chronic heart failure.
- Benefits are observed across diverse patient groups, including those with diabetes and renal failure.
Conclusions:
- Carvedilol demonstrates significant clinical benefits, including improved survival and reduced hospitalizations in heart failure.
- Its favorable safety profile and efficacy in comorbid patients support its use.
- Carvedilol is recommended in heart failure guidelines and should be widely implemented.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...